ALERT

Serious adverse effects resulting from the treatment with thalidomide prompted modern drug legislation more than 40 years ago. Post-marketing spontaneous reporting systems for suspected adverse drug reactions (ADRs) have been a cornerstone to detect safety signals in pharmacovigilance. It has become evident that adverse effects of drugs may be detected too late, when millions of persons have already been exposed.

In this project, an alternative approach for the detection of ADR signals will be developed. Rather than relying on the physician's capability and willingness to recognize and report suspected ADRs, the system will systematically calculate the occurrence of disease (potentially ADRs) during specific drug use based on data available in electronic patient records. In this project, electronic health records (EHRs) of over 30 million patients from several European countries will be available. In an environment where rapid signal detection is feasible, rapid signal assessment is equally important. To rapidly assess signals, a number of resources will be used to substantiate the signals: causal reasoning based on information in the EHRs, semantic mining of the biomedical literature, and computational analysis of biological and chemical information (drugs, targets, anti-targets, SNPs, pathways, etc.).

The overall objective of this project is the design, development and validation of a computerized system that exploits data from electronic healthcare records and biomedical databases for the early detection of adverse drug reactions. The ALERT system will generate signals using data and text mining, epidemiological and other computational techniques, and subsequently substantiate these signals in the light of current knowledge of biological mechanisms and in silico prediction capabilities. The system should be able to detect signals better and faster than spontaneous reporting systems and should allow for identification of subpopulations at higher risk for ADRs.

For further information, please visit:

Project co-ordinator:
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

Partners:

  • SOCIETA SERVIZI TELEMATICI SRL
  • UNIVERSIDADE DE AVEIRO
  • THE UNIVERSITY OF NOTTINGHAM
  • PHARMO COOPERATIE UA
  • AARHUS UNIVERSITETSHOSPITAL, AARHUS SYGEHUS
  • UNIVERSIDADE DE SANTIAGO DE COMPOSTELA
  • UNIVERSITAT POMPEU FABRA
  • IRCCS CENTRO NEUROLESI BONINO PULEJO
  • FUNDACIO IMIM
  • LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
  • ASTRAZENECA AB
  • UNIVERSITE VICTOR SEGALEN BORDEAUX II
  • AGENZIA REGIONALE DI SANITA
  • UNIVERSITA DEGLI STUDI DI MILANO - BICOCCA

Timetable: from 02/2008 – to 07/2011

Total cost: € 5.880.600

EC funding: € 4.500.000

Programme Acronym: FP7-ICT

Subprogramme Area: Advanced ICT for risk assessment and patient safety

Contract type: Collaborative project (generic)

Related news article:

Most Popular Now

Open Call SC1-DTH-01-2019: Big Data and …

Currently available methods and strategies for diagnosis and treatment of cancer help clinicians continuously improve quality of care and prevent cancer deaths in the population. Accurate risk assessment, availability of...

Cerner Selected for NHS Framework to Sup…

Integrated Care Systems (ICS) and Sustainability and Transformation Partnerships (STPs) aim to deliver the best possible quality of health and care, shift to value-based care and proactively improve outcomes for...

Brainlab and Magic Leap Partner in Digit…

Brainlab has announced a strategic development partnership with Florida-based Magic Leap, a developer of proprietary spatial computing solutions that help users enrich their real world experience by integrating digital content...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Satellites...

Whole-Brain Connectome Maps Teach Artifi…

Medical University of South Carolina (MUSC) neurologists have developed a new method based on artificial intelligence that may eventually help both patients and doctors weigh the pros and cons of...

Oxehealth Secures World-First Accreditat…

The British Standards Institute (BSI) has accredited Oxehealth's vital signs measurement software as a Class IIa medical device in Europe. This is the first time that software enabling a digital...

MEDICA 2018: The Starting Block for Many…

12 - 15 November 2018, Düsseldorf, Germany. MEDICA, the world’s leading medical trade fair in Düsseldorf which attracts over 5,000 exhibitors from around 70 countries, is becoming an even bigger hotspot...

MEDICA 2018 Presents the Future of Medic…

12 - 15 November 2018, Düsseldorf, Germany. Artificial intelligence, Big Data or IoT (Internet of Things) - we would be hard pressed to find a sector that doesn’t have these terms...

Artificial Intelligence for Health: ITU …

The ITU Focus Group on 'AI for Health' (FG-AI4H), created in collaboration with the World Health Organization (WHO), has issued a Call for Proposals to identify compelling use cases of...

Siemens Healthineers and STORZ MEDICAL P…

On the occasion of the 70th annual congress of the German Society for Urology, DGU, Siemens Healthineers and STORZ MEDICAL have announced plans to enter into a sales partnership agreement...

Spinal Cord Stimulation, Physical Therap…

Spinal cord stimulation and physical therapy have helped a man paralyzed since 2013 regain his ability to stand and walk with assistance. The results, achieved in a research collaboration between...

Sandoz Healthcare Access Challenge #Sand…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global competition that invites entrepreneurs and innovators...